- Home
- DXR vs MNOV Comparison
DXR vs MNOV Comparison
Compare DXR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | MNOV |
|---|---|---|
| Founded | 1970 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 69.4M |
| IPO Year | 1995 | 2004 |
Fundamental Metrics
Financial Performance| Metric | DXR | MNOV |
|---|---|---|
| Price | $9.26 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 2.2K | ★ 23.2K |
| Earning Date | 02-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,446,345.00 | ★ $2,360,807.00 |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | $180.00 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $8.45 | $1.17 |
| 52 Week High | $14.76 | $1.96 |
Technical Indicators
Market Signals| Indicator | DXR | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 38.42 | 31.70 |
| Support Level | $9.21 | $1.22 |
| Resistance Level | $11.40 | $1.32 |
| Average True Range (ATR) | 0.68 | 0.04 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 0.00 | 12.50 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.